Amgenvs.BioMarin Pharmaceutical
AMGN vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 17× larger than BioMarin Pharmaceutical by market cap; Amgen trades at the lower P/E (25.8 vs 183.0); year to date, Amgen leads (+35.6% vs +9.5%).
Side by side
| AMGN | BMRN | |
|---|---|---|
| Market cap | $226B | $13.4B |
| Price | $442.24 | $66.12 |
| Today | −0.4% | +1.6% |
| Return YTD | +35.6% | +9.5% |
| Return 1Y | +51.1% | +11.1% |
| P/E | 25.8 | 183.0 |
| P/S | 5.9 | 3.9 |
| P/B | 19.3 | 2.1 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →More AMGN & BMRN comparisons
Other head-to-heads in the Biotech & innovation segment.